EP4171532A1 - Combinaison stable de vildagliptine et de metformine hci - Google Patents

Combinaison stable de vildagliptine et de metformine hci

Info

Publication number
EP4171532A1
EP4171532A1 EP21828954.4A EP21828954A EP4171532A1 EP 4171532 A1 EP4171532 A1 EP 4171532A1 EP 21828954 A EP21828954 A EP 21828954A EP 4171532 A1 EP4171532 A1 EP 4171532A1
Authority
EP
European Patent Office
Prior art keywords
sodium
vildagliptin
tablet formulation
formulation according
mixtures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21828954.4A
Other languages
German (de)
English (en)
Inventor
Vildan TOMBAYOGLU
Yildiz Gulkok
Arzu PALANTOKEN
Fatih Sunel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of EP4171532A1 publication Critical patent/EP4171532A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Definitions

  • the present invention relates to a tablet formulation comprising vildagliptin and metformin hydrochloride wherein vildagliptin and at least one acidifying agent is dissolved in a solvent.
  • the present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient process.
  • Diabetes mellitus is a group of disorders of carbohydrate metabolism in which the action of insulin is diminished or absent through altered secretion, decreased insulin activity or a combination of both factors.
  • Type 1 and Type 2 There are two main types of diabetes; Type 1 and Type 2:
  • Type 1 diabetes occurs because the insulin-producing cells of the pancreas (beta cells) are damaged. In Type 1 diabetes, the pancreas makes little or no insulin, so sugar cannot get into the body's cells for use as energy. People with Type 1 diabetes must use insulin injections to control their blood glucose.
  • Type 2 diabetes the pancreas makes insulin, but it either doesn't produce enough, or the insulin does not work properly. This diabetes occurs most often in people who are over 40 years old and overweight. Type 2 diabetes may sometimes be controlled with a combination of diet, weight management, and exercise. However, treatment also may include oral glucose-lowering medications or insulin injections.
  • Vildagliptin is a dipeptidyl dipeptidase-IV (DPP-IV) inhibitor developed for use in the treatment of type 2 diabetes (non-insulin dependent diabetes).
  • DPP-IV dipeptidyl dipeptidase-IV
  • vildagliptin inhibits the degradation of the dipeptidyl dipeptidase-IV enzyme, thereby inhibiting the effects of incretin hormones, glucagon-like peptide-1 (GLP-1), and of glucose-dependent insulinotropic peptide (GIP).
  • GLP-1 glucagon-like peptide-1
  • GIP glucose-dependent insulinotropic peptide
  • the chemical designation of vildagliptin is (S)- ⁇ [(3-hydroxyadamantan-1- yl)amino]acetyl ⁇ pyrrolidine-2-carbonitrile, with the chemical structure illustrated below in Formula 1 .
  • Formula 1 Vildagliptin is soluble in water and in organic polar solvents.
  • Vildagliptin is marketed under the trademark Galvus ® in 50 mg dosage forms. It is used against diabetes mellitus, but particularly in treating type 2 diabetes.
  • Metformin is antidiabetics having an orally-administrated biguanide structure.
  • Metformin hydrochloride is a white to off-white crystalline compound and it is freely soluble in water and practically insoluble in acetone, ether and chloroform.
  • Oral doses of metformin are generally recommended in the range of 500 to 2500 mg a day and a single dose may vary from 500 to 850 mg. It is used singly or in combination with sulfonylureas, alpha-glucosidase inhibitors, or insulin.
  • metformin hydrochloride is 1 ,1-dimethylbiguanide hydrochloride, has the following chemical structure of Formula II.
  • Combination product of vildagliptin and metformin hydrochloride is marketed under the trademark Eucreas® (50mg/850mg and 50mg/1000mg dosage forms of vildagliptin and metformin hydrochloride).
  • Eucreas® 50mg/850mg and 50mg/1000mg dosage forms of vildagliptin and metformin hydrochloride.
  • a tablet disclosed can contain, in addition to the active substances, usual excipients, for example fillers, binders, disintegrants, lubricants and colorants.
  • lubricants that are mentioned are colloidal silica, magnesium trisilicate, starch, talc, calcium phosphate, magnesium stearate, aluminium stearate, calcium stearate, magnesium carbonate, magnesium oxide, polyethylene glycol, cellulose and microcrystalline cellulose.
  • EP2477660 (A1) discloses a pharmaceutical composition
  • a pharmaceutical composition comprising an active agent metformin or its salt in combination with an active agent sitagliptin or vildagliptin or their salt, and a lubricant (more than 10 wt.%, based on the total weight of the composition).
  • the lubricant is polyethylene glycol or a mixture of polyethylene glycol with at least one of the other lubricant.
  • vildagliptin Both metformin HCI and vildagliptin have some structural problems. Stability-related problems do occur in many active agents, including vildagliptin, under the influence of ambient and physical conditions.
  • Vildagliptin is an active agent that is highly-susceptible to air and humidity. When vildagliptin is exposed to air and humidity, it degrades structurally and develops chemical behavioral changes. The stability of vildagliptin products developed is not at a desired level and the shelf life thereof is shortened.
  • vildagliptin is reactive against the excipients employed in developing formulations containing the same. This fact causes impurities to occur in the formulation and leads to the inclusion of undesired components into the formulation.
  • vildagliptin salt was obtained and that it was tested while preparing the formulation and it was seen that is advantageous in that they show no measurable water absorption or loss. So, in this way was prevented degrade of vildagliptin and provided stabilizing of formulation.
  • vildagliptin and at least one acidifying agent is dissolved in a solvent and then vildagliptin salt is obtained. So, this formulation overcomes the above problems. In this way, starting with improved constancy of the physical parameters, an even higher quality of the formulations can be guaranteed.
  • the main object of the present invention is to provides a tablet comprising vildagliptin and metformin HCI capable of being compressed into a tablet having desired stability, rapid disintegration time and an acceptable dissolution profile.
  • Another object of the present invention is to eliminate problems and bringing additional advantages to the relevant prior art.
  • the main object of the present invention is to provides a process for a stable combination. The process is a simple, rapid, cost effective, time-saving and industrially convenient method.
  • solution means a form comprising vildagliptin, at least one acidifying agent and at least one binder are dissolved in a solvent, preferably 65% ethyl alcohol- water.
  • a tablet formulation comprises vildagliptin in a solution and metformin hydrochloride wherein the solution comprising dissolving vildagliptin and dissolving at least one acidifying agent and dissolving at least one binder in a solvent.
  • vildagliptin and at least one acidifying agent is dissolved in a solvent and then vildagliptin salt is obtained.
  • stability of the tablet formulation is provided, because vildagliptin salt is advantageous in that they show no measurable water absorption or loss and the active agent, vildagliptin, does not undergo degrade. This property is crucial in manufacture.
  • the solution comprising vildagliptin salts was used directly in the process without the need for crystallization. This allowed us to save time without using solvent. Thus, a stable combination was achieved a fast, practical and cheap.
  • vildagliptin salt helps to improve stability and dissolution profile when contained in a formulation comprising a further active ingredient, metformin HCI. Surprisingly, in the present invention, it was seen that the vildagliptin salt is also have the advantage to avoid or reduce the degradation of the further active ingredient.
  • Suitable acidifying agent is selected from the group comprising hydrochloric acid, citric acid, citric acid anhydrate, tartaric acid, ascorbic acid, malic acid, oxalic acid, succinate, acetic acid, butyric acid, malonic acid, formic acid, fumaric acid or mixtures thereof.
  • the amount of acidifying agent is between 0.1% and 5.0% by weight in the total formulation.
  • the amount of the acidifying agent in is from 1 mole to 1.5 moles per mole of the vildagliptin, preferably from 1.0 to 1.3 moles per mole of the vildagliptin. This proportions are very important for the preparation of vildagliptin salt, therefore for a stable combination.
  • the acidifying agent is hydrochloric acid.
  • Suitable binders are selected from the group comprising polyvinylpyrrolidone, hydroxypropyl methyl cellulose, sodium carboxymethyl cellulose, polyethylene glycol, polyvinyl alcohol, polyvinyl acetate, pregelatinized starch, natural gums, sucrose, sodium alginate, carboxy methyl cellulose, methyl cellulose, gelatin, carrageenan, guar gum, carbomer, polymethacrylates, methacrylate polymers, gelatin, agar, alginate, xanthan gum, pectin, polysaccharides, carbomer, poloxamer, polyacrylamide, aluminum hydroxide, laponite, bentonite, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
  • the use of binders provides easy distribution of the solution in the formulation. So, it helps to provide the desired dissolution profile in the formulation.
  • the amount of binders is between 1 .0% and 20.0% by weight in the total formulation. Preferably, it is between 2.0% and 10.0% or 3.0% and 7.0% by weight in the total formulation.
  • the binder is polyvinylpyrrolidone or hydroxypropyl methyl cellulose or mixtures thereof.
  • preparing the solution comprises the following steps;
  • the amount of metformin hydrochloride is between 50.0% and 90.0% by weight in the total formulation. Preferably, it is between 60.0% and 80.0% by weight in the total formulation.
  • the amount of vildagliptin is between 2.0% and 20.0% by weight in the total formulation. Preferably, it is between 2.0% and 10.0% or 2.0% and 7.0% by weight in the total formulation.
  • a tablet comprises at least one pharmaceutically acceptable excipient which is selected from the group comprising fillers, disintegrants, lubricants, glidants, surfactants, anti-caking agent, coating agents or mixtures.
  • excipients provided in a formulation may positively or negatively influence the physicochemical and pharmacokinetic properties, e.g. the solubility, absorption, bioavailability of an active agent. For this reason, the excipients which accompany an active agent have to be selected in a careful and conscious manner while a formulation is developed.
  • the formulations should have no physicochemical incompatibility between the active agents and the excipients.
  • Suitable fillers are selected from the group comprising microcrystalline cellulose, dibasic calcium phosphate, mannitol, spray-dried mannitol, lactose, lactose monohydrate, starch, dextrose, sucrose, fructose, sodium carbonate, maltose, sorbitol, xylitol, inositol, kaolin, inorganic salts, calcium salts, polysaccharides, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium bicarbonate, calcium carbonate or mixtures thereof.
  • the amount of fillers is between 2.0% and 20.0% by weight in the total formulation. Preferably, it is between 2.0% and 10.0% or 3.0% and 7.0% by weight in the total formulation.
  • the filler is microcrystalline cellulose.
  • Suitable disintegrants are selected from the group comprising croscarmellose sodium, sodium starch glycolate, pregelatinized starch, low-substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, polyacryline potassium, sodium alginate, corn starch, alginates, ion-exchange resins, magnesium aluminum silicate, sodium dodecyl sulphate, poloxamer, sodium glycine carbonate or mixtures thereof.
  • the amount of disintegrants is between 2.0% and 10.0% by weight in the total formulation.
  • the disintegrant is croscarmellose sodium or sodium starch glycolate or mixtures thereof.
  • Suitable lubricants are selected from the group comprising from sodium stearyl fumarate, magnesium stearate, calcium stearate, zinc stearate, waxes, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, glycerol palmito sulphate or mixtures thereof.
  • the amount of lubricants is between 0.5% and 5.0% by weight in the total formulation.
  • the lubricant is sodium stearyl fumarate or magnesium stearate or mixtures thereof.
  • Suitable glidants are selected from the group comprising colloidal silicon dioxide, corn starch or mixtures thereof.
  • the amount of glidants is between 0.1% and 2.0% by weight in the total formulation.
  • the glidant is colloidal silicon dioxide.
  • Suitable surfactants are selected from the group comprising sodium lauryl sulphate, sodium docusate, glyceryl monooleate, polyethylene alkyl ether, polyoxyethylene stearates, polyethylene glycol, sodium benzoate, docusate sodium, alpha tocopherol, ascorbyl palmitate, polyoxyethylene hydrogenated castor oil or mixtures thereof.
  • the amount of surfactants is between 0.1% and 2.0% by weight in the total formulation.
  • the surfactant is sodium lauryl sulphate.
  • Suitable anti-caking agent is selected from the group comprising talc, calcium phosphate, tribasic, calcium silicate, hydrophobic colloidal silica, magnesium oxide, magnesium silicate, magnesium trisilicate or mixtures thereof.
  • the anti-caking agent is talc.
  • the amount of anti-caking agent is between 0.01% and 3.0% by weight in the total formulation.
  • Suitable coating agents are selected from the group comprising copovidone, polymethacrylates, polydextrose, polyalkylacrylates copolymers, triacetin, hydroxyl propyl methyl cellulose, colloidal silicon dioxide, lactose monohydrate, medium chain triglycerides, hydroxypropyl cellulose, white wax, polyvinyl alcohol, polyethylene glycol, talc, polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat® IR), ethylcellulose dispersions (Surelease®), polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA), all kinds of Opadry®, pigments, dyes, titanium dioxide, red iron oxide, black iron oxide or mixtures thereof. According to one embodiment of the present invention, the amount of coating comprising coating agents is between 2.0% and 5.0% by weight in the total formulation.
  • the coating agents are polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, red iron oxide, black iron oxide or mixture thereof.
  • the tablet of the present invention may be prepared, using standard techniques and manufacturing processes well known in the art, such as direct compression, granulation wet or dry granulation, hot melt granulation, hot melt extrusion, fluidized bed granulation, extrusion/spheronization, slugging, spray drying and solvent evaporation.
  • Example 1 The tablet formulation comprising vildagliptin and metformin HCI
  • Example 2 The tablet formulation comprising vildagliptin and metformin HCI
  • Adding microcrystalline cellulose and croscarmellose sodium and then mixing and obtained a powder mixture Preparing the solution o Adding vildagliptin in a solvent, preferably 65% ethyl alcohol- water, o Then, adding hydrochloric acid (37.0% hydrochloric acid-water) and mixing, o Then, adding polyvinylpyrrolidone and mixing.
  • a solvent preferably 65% ethyl alcohol- water
  • hydrochloric acid 37.0% hydrochloric acid-water
  • Example 3 The tablet formulation comprising vildagliptin and metformin HCI
  • Example 4 The tablet formulation comprising vildagliptin and metformin HCI

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente Invention concerne une formulation de comprimé comprenant de la vildagliptine et du chlorhydrate de metformine, la vildagliptine et au moins un agent acidifiant étant dissous dans un solvant. La présente invention concerne également un procédé simple, rapide, économique, économe en temps et industriellement commode.
EP21828954.4A 2020-06-25 2021-05-07 Combinaison stable de vildagliptine et de metformine hci Pending EP4171532A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2020/09946A TR202009946A2 (tr) 2020-06-25 2020-06-25 Vi̇ldagli̇pti̇n ve metformi̇n hci i̇çeren bi̇r stabi̇l kombi̇nasyon
PCT/TR2021/050442 WO2021262115A1 (fr) 2020-06-25 2021-05-07 Combinaison stable de vildagliptine et de metformine hci

Publications (1)

Publication Number Publication Date
EP4171532A1 true EP4171532A1 (fr) 2023-05-03

Family

ID=79281619

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21828954.4A Pending EP4171532A1 (fr) 2020-06-25 2021-05-07 Combinaison stable de vildagliptine et de metformine hci

Country Status (3)

Country Link
EP (1) EP4171532A1 (fr)
TR (1) TR202009946A2 (fr)
WO (1) WO2021262115A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3086781B1 (fr) * 2013-12-23 2023-09-13 KRKA, d.d., Novo mesto Composition pharmaceutique d'un inhibiteur de la dpp iv en combinaison avec la metformine
MA40869A (fr) * 2014-10-30 2017-09-05 Sanovel Ilac Sanayi Ve Ticaret As Combinaisons pharmaceutiques de vildagliptine et d'agonistes de ppar
CN105193752B (zh) * 2015-10-27 2018-03-30 石家庄康贺威药业有限公司 一种维格列汀片剂及其制备方法

Also Published As

Publication number Publication date
TR202009946A2 (tr) 2022-01-21
WO2021262115A1 (fr) 2021-12-30

Similar Documents

Publication Publication Date Title
CN110548026B (zh) 含有葡萄糖激酶激活剂和k-atp通道阻断剂的药物组合及其制备方法和用途
EP2468268B1 (fr) Composition de combinaison de vildagliptine et de gliclazide
US20180000792A1 (en) Modified release compositions of epalrestat or a derivative thereof and methods for using the same
WO2019194773A2 (fr) Combinaison contenant de la linagliptine et de la metformine
EP3781135A2 (fr) Compositoins pharmaceutiques solides d'administration par voie orale comprenant de la sitagliptine
EP3976014A1 (fr) Combinaison comprenant de l'alogliptine et de la metformine
US20150283248A1 (en) Pharmaceutical compositions of Linagliptin and process for preparation thereof
WO2021045706A1 (fr) Combinaison comprenant de la vildagliptine et de la metformine
WO2021262116A1 (fr) Comprimé pelliculé comprenant de la vildagliptine et de la metformine hci
EP4171532A1 (fr) Combinaison stable de vildagliptine et de metformine hci
WO2021246985A1 (fr) Procédé de préparation d'un comprimé pelliculé comprenant de la linagliptine et de la metformine
EP2468256B1 (fr) Combinaisons de vildagliptine et de glimépiride
WO2019132833A1 (fr) Combinaison à libération modifiée comprenant de la linagliptine et de la metformine
WO2022035400A1 (fr) Formulation de comprimé comprenant de la sitagliptine et de la metformi̇ne
WO2022173406A1 (fr) Procédé pour formulations de linagliptine ou d'un sel pharmaceutiquement acceptable de celle-ci
WO2022119541A1 (fr) Formulation de comprimé pelliculé comprenant de la dapagliflozine et du chlorhydrate de metformine
EP4079296A1 (fr) Formulation de comprimé bicouche comprenant de la dapagliflozine amorphe et de la metformine
WO2022119540A2 (fr) Procédé pour formulations de dapagliflozine et de chlorhydrate de metformine
EP4212150A1 (fr) Composition de comprimé bicouche comprenant de la dapagliflozine amorphe et de la metformine
WO2023136797A2 (fr) Composition de comprimé bicouche comprenant de la metformine et de la dapagliflozine amorphe

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230708

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)